Longeveron Inc. Discloses Nasdaq Non-Compliance Due to Audit Committee Financial Expert Vacancy

summarizeSummary

Longeveron Inc. reported non-compliance with Nasdaq listing rules after its audit committee financial expert resigned, creating a vacancy the company plans to address within a 180-day cure period.

check_boxKey Events · Corporate Governance and Compliance · LGVN

• Nasdaq Non-Compliance

  The company is non-compliant with Nasdaq Listing Rule 5605(c)(2)(A) due to the lack of an audit committee financial expert.

• Director Resignation

  Mr. Richard Kender resigned from the Board and Audit Committee, citing a new role at Seres Therapeutics, not a disagreement with Longeveron.

• Audit Committee Appointment

  Dr. Roger Hajjar, an existing Board member, was appointed to the Audit Committee to maintain the required number of independent directors.

• Cure Period Initiated

  Longeveron has a 180-day period to regain compliance by appointing a qualified audit committee financial expert.

auto_awesomeAnalysis · LGVN · Life Sciences

This 8-K filing highlights a significant corporate governance challenge for Longeveron Inc., which is already navigating a proposed reverse stock split to maintain its Nasdaq listing. The resignation of Mr. Richard Kender, the audit committee financial expert, has left the company non-compliant with Nasdaq Listing Rule 5605(c)(2)(A). While the company has appointed an existing board member to the audit committee to meet the independent director count, the critical role of a financial expert remains unfilled. The company has a 180-day cure period to appoint a new independent financial expert, but this adds another layer of uncertainty to its listing status and raises concerns about financial oversight.